• KOL
    • Lung Cancer
    • Ritsuko R Komaki
    • Ritsuko R Komaki: Influence Statistics

      Ritsuko R Komaki

      Ritsuko R Komaki

      Show email address

      Baylor College of Medicine, Houston, TX, United States. | The University of Texas MD Anderson Cancer Center, Houston, TX; | Department of Radiation Oncology, The University of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Ritsuko R Komaki:Expert Impact

      Concepts for whichRitsuko R Komakihas direct influence:Lung cancer,Cell lung,Radiation therapy,Esophageal cancer,Small cell,Induction chemotherapy,Concurrent chemotherapy,Brain metastases.

      Ritsuko R Komaki:KOL impact

      Concepts related to the work of other authors for whichfor which Ritsuko R Komaki has influence:Lung cancer,Small cell,Radiation therapy,Brain metastases,Elderly patients,Computed tomography.

      KOL Resume for Ritsuko R Komaki

      Year
      2021

      Baylor College of Medicine, Houston, TX, United States.

      The University of Texas MD Anderson Cancer Center, Houston, TX;

      2020

      Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA

      Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston

      2019

      Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

      2018

      Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030

      Zhongxing Liao, J. Jack Lee, Ritsuko Komaki, Daniel R. Gomez, Michael S. O'Reilly, Frank V. Fossella, George R. Blumenschein Jr, John V. Heymach, Ara A. Vaporciyan, Stephen G. Swisher, Pamela K. Allen, Stephen M. Hahn, James D. Cox, Charles S. Lu, and Radhe Mohan, The University of Texas MD Anderson Cancer Center, Houston, TX; and Noah Chan Choi and Thomas F. DeLaney, Massachusetts General Hospital and Harvard Medical School, Boston, MA.

      MD Anderson Cancer Center, Houston, Texas.

      2017

      Radiation Oncology, MD Anderson Cancer Center, Houston, TX/US

      MD Anderson Cancer Center, Houston, TX;

      2016

      The University of Texas MD Anderson Cancer Center

      2015

      Departments of, Gastrointestinal Medical Oncology, Biostatistics, Gastroenterology, Hepatology, and Nutrition, Radiation Oncology, Thoracic and Cardiovascular Surgery, Pharmacy and, Pathology, The University of Texas MD Anderson Cancer Center, Houston, Tex., USA

      Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York (A.B.L. current); Memorial Sloan Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National Cancer Institute/National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current); Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.); NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.)

      2014

      Department of Radiation Oncology, The University of Texas MD, Anderson Cancer Center, Houston, TX

      2013

      The University of Texas MD Anderson Cancer Center Department of Radiation Oncology Houston Texas USA

      Universityof Texas MD Anderson Cancer Center, Houston, TX

      2012

      Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA

      University of Texas M. D. Anderson Cancer Center, Houston, TX; The University of Michigan, Ann Arbor, MI

      M.D. Anderson Cancer Center, Houston, TX

      2011

      Affiliations of authors: Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA (WJC); Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA (RP); Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA (CJL); Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (RK, JDC); Lung Cancer Branch, National Cancer Center, Kyonggi, Korea (JSL); Formerly of University of California at San Francisco, San Francisco, CA (SH); Department of Radiation Oncology, Hartford Hospital Gray Cancer Center, Hartford, CT (SH); Formerly of Fox Chase Cancer Center, Philadelphia, PA (BM); Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI (BM); Department of Radiation Oncology, Washington University, St Louis, MO (TW); Radiological Associates of Sacramento, Sacramento, CA (SAR); Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI (EG); Department of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, OH (MM); Department of Radiation Oncology, Intermountain Medical Center, Murray, UT (WS)

      Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX

      The University of Texas MD Anderson Cancer Center, Houston

      2010

      Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA

      M. D. Anderson Cancer Center, Houston, TX

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Ritsuko R Komaki is among the top experts in the world.
      Concept World rank
      mva pet #1
      pfs rpa #1
      compared imrt #1
      bid 261 patients #1
      etn wbrt srs #1
      lsclc #1
      radiation dose 838 #1
      sbrt august #1
      incidence trp #1
      lung feasibility #1
      tgfbeta1 rs1982073 #1
      709 1 case #1
      dct50 #1
      period survey #1
      1547 patients #1
      sclc patients pci #1
      strt2 #1
      definitive chemotherapy #1
      surveys review #1
      dlco local dose #1
      seg1 seg1r #1
      hspb1 hspb1 rs2868371 #1
      rp dlco #1
      increased fdg heart #1
      local disease progression #1
      dna ki67 #1
      enf nsclc #1
      dct0 #1
      shaakekonig #1
      212months #1
      58 fractions #1
      failure patterns chemotherapy #1
      study national patterns #1
      qale mild severity #1
      010094cm #1
      ebhct #1
      kps suv2 #1
      brain metastases pci #1
      acrt iii nsclc #1
      amifostine acute toxicity #1
      ict cct #1
      enf isolated enf #1
      ncrt basis #1
      tmt patients survival #1
      043263cm #1
      outcome stage iii #1
      v20 prd #1
      treatmentrelated pneumonitis #1
      induction chemotherapy dcrt #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Ritsuko R Komaki

      KOL-Index: 28764

      BACKGROUND: We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer.

      METHODS: In this open-label randomised, two-by-two factorial phase 3 study in 185 institutions in the USA and Canada, we enrolled patients (aged ≥ 18 years) with unresectable stage III non-small-cell lung cancer, a Zubrod ...

      Known for Conformal Radiotherapy | Patients Cetuximab | Cell Lung | Rtog 0617 | 3 Study
      KOL-Index: 24631

      BACKGROUND: The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these ...

      Known for Operable Stage | Sabr Surgery | Pooled Analysis | Randomised Trials | Cell Lung
      KOL-Index: 20422

      PURPOSE: To assess the association of clinical and especially dosimetric factors with the incidence of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiation therapy followed by surgery.

      METHOD AND MATERIALS: Data from 110 esophageal cancer patients treated between January 1998 and December 2003 were analyzed retrospectively. All patients received concurrent chemoradiotherapy followed by surgery; 72 patients also received ...

      Known for Dosimetric Factors | Pulmonary Complications | Esophageal Cancer Patients | Volume Lung | Multivariate Analysis
      KOL-Index: 19000

      BACKGROUND: Patients with locoregional carcinoma of the esophagus or gastroesophageal junction have a poor survival rate after surgery. Preoperative chemotherapy or chemoradiotherapy has not improved the outcome for these patients. Our study was designed to assess the feasibility of preoperative induction combination chemotherapy in addition to chemoradiotherapy to improve the curative resection rate, local control, and survival. PATIENTS AND METHODS Patients having histologic proof of ...

      Known for Gastroesophageal Junction | Induction Chemotherapy | Surgery Patients | Resectable Carcinoma | Continuous Infusion
      KOL-Index: 18102

      PURPOSE: The purpose of this study was to assess response, toxicity, failure patterns, and survival differences in three chemotherapy (ChT)/radiation therapy (RT) sequencing strategies for locally advanced non-small cell lung cancer (NSCLC).

      METHODS AND MATERIALS: Five completed Radiation Therapy Oncology Group (RTOG) trials for Stage II-IIIA/B inoperable NSCLC patients employed one of the three following strategy groupings: 1) sequential ChT followed by standard RT (60 Gy in 6 weeks); ...

      Known for Radiation Therapy | Late Toxicity | Cell Carcinoma | 2 3 | Concurrent Cht
      KOL-Index: 16986

      BACKGROUND: Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at sites of disease known to exist at baseline. However, the potential effect of aggressive local consolidative therapy for patients with oligometastatic NSCLC is unknown. We aimed to assess the effect of local consolidative therapy on progression-free survival.

      METHODS: In this multicentre, randomised, ...

      Known for Maintenance Therapy | Local Consolidative | Lung Cancer | Small Cell | Progressionfree Survival
      KOL-Index: 16649

      PURPOSE: To evaluate tumor resectability after induction chemotherapy and to determine disease-free and overall survival rates of patients with locally advanced unresectable thymoma that received a multimodal treatment regimen.

      PATIENTS AND METHODS: Twenty-two patients (9 men, 13 women) with histologically confirmed invasive thymoma were treated with a multidisciplinary regimen consisting of three courses of induction chemotherapy, surgical resection, and radiation therapy, followed by ...

      Known for Induction Chemotherapy | Radiation Therapy | Surgical Resection | Multidisciplinary Approach | 22 Patients
      KOL-Index: 16607

      PURPOSE: To evaluate prospectively the acute and late morbidities from a multiinstitutional three-dimensional radiotherapy dose-escalation study for inoperable non-small-cell lung cancer.

      METHODS AND MATERIALS: A total of 179 patients were enrolled in a Phase I-II three-dimensional radiotherapy dose-escalation trial. Of the 179 patients, 177 were eligible. The use of concurrent chemotherapy was not allowed. Twenty-five patients received neoadjuvant chemotherapy. Patients were stratified ...

      Known for Lung Carcinoma | V20 Patients | Conformal Radiotherapy | Escalation Study | Nodal Failure
      KOL-Index: 16456

      BACKGROUND: The current study was performed to assess the value of 2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in predicting the pathologic response and survival of patients with esophageal carcinoma treated with preoperative chemoradiation (CRT) and tumor resection. Preliminary reports suggest that FDG-PET may be predictive of the response of esophageal carcinoma patients to preoperative CRT.

      METHODS: Eighty-three patients with resectable esophageal carcinoma who ...

      Known for Pathologic Response | Esophageal Carcinoma | Preoperative Chemoradiation | Emission Tomography | Crt Fdgpet
      KOL-Index: 15689

      BACKGROUND: To evaluate the effects of administering chemotherapy following surgery, or following surgery plus radiotherapy (known as adjuvant chemotherapy) in patients with early stage non-small cell lung cancer (NSCLC),we performed two systematic reviews and meta-analyses of all randomised controlled trials using individual participant data. Results were first published in The Lancet in 2010.

      OBJECTIVES: To compare, in terms of overall survival, time to locoregional recurrence, time to ...

      Known for Adjuvant Chemotherapy | Surgery Radiotherapy | Cell Lung | Performance Status | Randomised Patients
      KOL-Index: 15488

      PURPOSE: In search of reliable biologic markers to predict the risk of normal tissue damage by radio(chemo)therapy before treatment, we investigated the association between single nucleotide polymorphisms (SNPs) in the transforming growth factor 1 (TGFbeta1) gene and risk of radiation pneumonitis (RP) in patients with non-small-cell lung cancer (NSCLC).

      PATIENTS AND METHODS: Using 164 available genomic DNA samples from patients with NSCLC treated with definitive radio(chemo)therapy, we ...

      Known for Definitive Radiotherapy | Radiation Pneumonitis | Cell Lung | Single Nucleotide | Tgfβ1 Gene
      KOL-Index: 15170

      PURPOSE: Intrathoracic recurrence of non-small cell lung cancer (NSCLC) after initial treatment remains a dominant cause of death. We report our experience using proton beam therapy and intensity modulated radiation therapy for reirradiation in such cases, focusing on patterns of failure, criteria for patient selection, and predictors of toxicity.

      METHODS AND MATERIALS: A total of 102 patients underwent reirradiation for intrathoracic recurrent NSCLC at a single institution. All doses ...

      Known for Proton Beam Therapy | Cell Lung | Intensity Modulated | Local Organs | Definitive Reirradiation

      Key People For Lung Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #3
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #4
      Jacques Ferlay
      cancer incidence global burden latin america
      #5
      Adi F Gazdar
      lung cancer cell lines aberrant methylation
      #6
      Frances Alice Shepherd
      lung cancer small cell adjuvant chemotherapy

      Baylor College of Medicine, Houston, TX, United States. | The University of Texas MD Anderson Cancer Center, Houston, TX; | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.